SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company, which focuses on the discovery, acquisition, and development of small molecules and biologics to treat and prevent human disease and alleviate suffering. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and TNX-1800. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in Chatham, NJ.

Tonix Pharmaceuticals Holding Corp

TNXP is trending as the launch of their fibromyalgia drug, TONMYA, nears, with discussions focusing on its potential impact and market penetration. The community is debating the significance of institutional ownership and analyzing the company's financial health in relation to the upcoming commercial execution. Anticipation of revenue generation and a possible short squeeze are also fueling interest.

Luckin Coffee, Inc. engages in providing food and beverage items, and operates coffee retail stores. It has a pioneered a technology-driven retail network to provide coffee and other products of high quality, high convenience and high affordability to customers. The company manages pick-up stores, relax stores, and delivery kitchens. It also offers tea, snacks, and light meals through its mobile application. The company was founded by Zhi Ya Qian, Fei Yang and Jin Yi Guo on June 16, 2017 and is headquartered in Xiamen, China.

Luckin Coffee Inc - ADR

Luckin Coffee is trending due to recent earnings report indicating a 50% YoY revenue increase and record customer growth, although margins were pressured by higher delivery expenses. Community discussion revolves around the impressive revenue numbers and store expansion, with some expressing concern over margin decline and a lack of updates regarding a potential US relisting. Overall, while growth is undeniable, the sustainability of margins and potential catalysts like relisting are key talking points.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class C

Alphabet is trending after Berkshire Hathaway disclosed a $4.3 billion stake, fueling optimism and driving shares up. The community is discussing whether this move signals a broader shift in Warren Buffett's investment strategy towards tech and AI, while others debate the valuation and potential for further gains. This news coincides with Alphabet's ongoing investments in data centers to support cloud and AI initiatives.

Zymeworks, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Its product includes Zanidatamab, which is a novel bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2). Zanidatamab's unique binding properties result in multiple mechanisms of action that may enable it to address unmet need in patient populations with HER2-expressing cancers. The company was founded on September 8, 2003 and is headquartered in Middletown, DE.

Zymeworks BC Inc

Zymeworks Inc

ZYME is trending following positive Phase 3 trial results for their cancer treatment Ziihera, developed in partnership with Jazz Pharmaceuticals. The community is discussing the potential impact on HER2-positive cancers and the financial implications for both ZYME and Jazz. Some traders caution about low trading volume and the potential risks of getting in now.

Sigma Lithium Corp. engages in the producing of a lithium property. It focuses its project in Minas Gerais. The firm also plans to build a world-class commercial-scale lithium concentration plant. The company was founded on June 8, 2011 and is headquartered in Sao Paulo, Brazil.

Sigma Lithium Corporation

Sigma Lithium ($SGML) is trending amid discussions around lithium prices, production capacity, and potential takeover scenarios. Community members are analyzing the impact of fluctuating lithium prices on the company's future earnings and debating whether recent price movements signal a potential sector recovery, while also noting insider buying activity. Some traders discuss technical indicators and potential short squeezes, while cautioning of continued volatility given recent price action.

Grindr, Inc. engages in the operation of a social media network application for the gay, bi, trans, queer, and other members of the LGBTQ+ community. The company was founded in 2009 and is headquartered in West Hollywood, CA.

Grindr Inc - Ordinary Shares - Class A

Grindr Inc

Grindr is trending amid buyout speculation, with community members debating the likelihood of a deal and potential premium. Discussions also involve insider selling and its impact on a possible acquisition. Despite the uncertainty, some believe GRND is undervalued, citing strong earnings and analyst price targets.

XPeng, Inc. engages in the design, development, manufacture, and marketing of smart electric vehicles. Its products are environmentally friendly vehicles, namely an SUV (the G3) and a four-door sports sedan (the P7). It also provides a range of services to the clients, including supercharging service, maintenance service, ride-hailing service and vehicle leasing service. The company was founded by Xiao Peng He, Heng Xia, and Tao He in 2015 and is headquartered in Guangzhou, China.

XPeng Inc - ADR

XPEV is trending due to positive developments in AI and robotics, including the unveiling of its 'Iron' humanoid robot, and expansion into new European markets. Community discussions revolve around the company's potential to surpass Tesla in robotics and its attractive valuation relative to its growth and innovation. Upcoming earnings are also a key point of interest, with investors anticipating strong results.

StarkNet is a permissionless decentralized Layer 2 (L2) validity rollup, built to allow Ethereum to scale via cryptographic protocols called STARKs, without compromising Ethereum’s core principles of decentralization, transparency, inclusivity and security. The StarkNet Token is needed to operate the ecosystem, maintain and secure it, decide on its values and strategic goals, and direct its evolution. This token will be required for (i) governance, (ii) payment of transaction fees on StarkNet, and (iii) participation in StarkNet’s consensus mechanism.

Strike Coin

Starknet (STRK) is trending as the community highlights its potential in BTCFi, staking, and overall ecosystem growth; a high percentage of the token supply being staked is a key factor. Some believe Starknet's technology, including the S-Two prover upgrade and focus on zero-knowledge proofs, positions it as a leader in Layer 2 scaling and privacy, drawing comparisons to Zcash (ZEC).

WeShop Holdings Ltd. engages in providing a shoppable social network. It offers shopping in fashion and accessories, health and beauty, home and DIY, food and drink, travel and holidays, tech and electronics, and other popular categories. It includes a library of shoppable product reviews from a digital online shopping mall on mobile devices. The company was founded by John Garner on September 21, 2012 and is headquartered in Jersey, the United Kingdom.

WeShop Holdings Ltd - Ordinary Shares - Class A

Wasatch Pharmaceutical Inc

Wasatch Pharmaceutical (WSHP) is trending due to its recent direct listing, with the community actively discussing potential entry points and watching for chart patterns. Some traders are pointing to the stock as a possible sympathy play, while others urge caution, calling it a scam.

Innodata, Inc. is a data engineering company, which engages in providing artificial intelligence software platforms and management of its services. It operates through the following business segments: Digital Data Solutions (DDS), Synodex, and Agility. The DDS segment combines deep neural networks and human expertise in multiple domains to make unstructured information useable. The Synodex segment enables clients in the insurance and healthcare sectors to transform medical records into useable digital data and to apply technologies to the digital data to augment decision support. The Agility segment provides tools and related professional services that enable public relations and communications professionals to discover influencers, amplify messages, monitor coverage, and measure the impact of campaigns. The company was founded by Todd H. Solomon in 1988 and is headquartered in Ridgefield Park, NJ.

Innodata Inc

Innodata's stock is trending due to community speculation around a potential joint strategic partnership announcement with a market leader, possibly Palantir, before the end of the year. The optimism is fueled by positive sentiments shared from an institutional contact, analysis of Jack's language during the earnings call, and suggestive technical chart patterns. This buzz is further amplified by Innodata's growing presence in government AI and sovereign AI initiatives.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

iBio, Inc. (IBIO) Reports Q1 Loss

iBio (IBIO) delivered earnings and revenue surprises of -57.14% and 0.00%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Shares of iBio, Inc.(IBIO) were in the spotlight on Monday after the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/04/07/3056559/0/en/iBio-Announces-IBIO-600-Non-Human-Primate-Data-Showing-Extended-Half-Life-and-Muscle-Growth-and-Interim-In-Vivo-Results-for-First-in-Class-Activin-E-Antibody-Advancing-Cardiometabo.html">announced</a> positive data from a study conducted in animals for its lead asset IBIO-600.The company said data from a study on elderly and obese non-human primates shows that the anti-myostatin antibody could provide a weight loss treatment option while preserving and promoting muscle growth.The study consisted of a single administration of two dose levels: 5mg/kg and a high dose of 50mg/kg.Shares of the company were down by over 43% on Monday noon amid a broader market decline.Notably, the study does not prove statistical significance and only involves a single administration of the antibody.However, the study demonstrated an extended half-life for the antibody, potentially enabling a once three to six-month dosing schedule in humans, the company said.CEO Martin Brenner said the company is on track for a regulatory submission for the antibody in the first quarter (Q1) of 2026.iBio in-licensed IBIO-600 from AstralBio, Inc. in January. The company paid AstralBio $750,000 by issuing its common stock as an upfront payment and said AstralBio will also be eligible for development and commercialization milestone payments totaling up to $28 million.On Monday, the company also announced preclinical data for an Activin E antibody and said that the antibody showed positive results in an exploratory study with obese mice, highlighting its potential as a treatment for obesity.On Stocktwits, retail sentiment about iBio remained in the ‘bearish’ territory while message volume rose marginally within ‘low’ levels over the past 24 hours.<figure class="image"><img style="aspect-ratio:654/152;" src="https://news.stocktwits-cdn.com/Screenshot_2025_04_07_at_11_29_58_AM_png_24aaec3e9f.webp" alt="IBIO's Sentiment Meter and Message Volume as of 11:30 a.m. ET on April 7, 2025 | Source: Stocktwits" width="654" height="152"><figcaption>IBIO's Sentiment Meter and Message Volume as of 11:30 a.m. ET on April 7, 2025 | Source: Stocktwits</figcaption></figure> A Stocktwits user expressed surprise at the stock’s downward trajectory.<stembedurl>https://stocktwits.com/Skypier2/message/610731384</stembedurl>Another opined that the company needs to protect itself against any potential hostile takeovers.<stembedurl>https://stocktwits.com/dcpanda/message/610733604</stembedurl><a href="https://stocktwits.com/symbol/IBIO">iBio shares</a> are down by over 24% this year and by over 19% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/federal-reserve-board-of-governors-will-meet-today/chf1DjqRb7o">Federal Reserve Board Of Governors Will Meet Today — Traders Factor In 4 Rate Cuts This Year</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

iBio Stock Plummets Despite Positive Data On Weight-Loss Treatment Antibody: Retail Stays Bearish

However, the company said that the study does not prove statistical significance and only involves a single administration of the antibody. 

Equity

Biotechs have underperformed the broader market this year, and these stock are at crossroads as they await the new administration under Donald Trump to take over shortly after the new year.The SPDR S&amp;P Biotech ETF ($XBI) has gained 9.2% for the year-to-date period compared to the 25%+ gain for the S&amp;P 500 Index. The iShares Biotechnology ETF ($IBB), which has a relatively higher proportion of mid- and large-cap stocks, has also added under 10% so far this year.The underperformance takes away the sheen of the industry’s defensive credentials.&nbsp;R&amp;D momentum slowed during the year, as is evident from the new molecular entity approvals, which number 38 so far this year compared to 47 for the same period last year.&nbsp;&nbsp;Most biotech companies operate deep in the red for a very long time until they could begin commercializing products. They rely on debt financing which came to be expensive in an elevated interest rate environment.&nbsp;With a change of guard on the political arena following Trump's win, the outlook for the industry is yet unclear.Morgan Stanley Head of Policy Monica Guerra&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.morganstanley.com/articles/trump-re-election-implications-for-markets">said&nbsp;</a>in a recent note that deregulation is likely to be a major theme expected during the second term. “Less stringent requirements in pharmaceuticals and biotechnology, meanwhile, could help those industries by prompting accelerated drug approvals,” she said.BMO Capital Markets analyst Evan Seigerman said the election results are “modestly positive” for the biopharma sector,&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.fiercepharma.com/pharma/trump-white-house-again-whats-ahead-pharma">according</a> to FiercePharma. The analyst sees potential deprioritization of the Internal Revenue Service, likely less Federal Trade Commission interference, and lower corporate taxes.Jefferies analysts does not expect the proposed drug pricing reforms to pass as the Republican legislators are divided over the proposals.Amid the ongoing discussions about the implications of Trump’s presidency, here’s a few biopharma stocks that are on retail’s radar (based on the number of followers on the Stocktwits platform):Moderna, Inc. ($ MRNA): 107,109 watchersNovavax, Inc. ($NVAX): 101,846Pfizer, Inc. ($PFE): 99,425 watchersiBio, Inc. ($IBIO): 93,617 watchersInovia Pharma, Inc. ($INO): 93,414 watchersJaguar Health ($JAGX): 81,859 watchersGilead Sciences, Inc. ($GILD): 77,094 watchersVaxart, Inc. ($VXRT): 75,807 watchersTonix Pharmaceutical Holding Corp. ($TNXP): 72,666 watchersSorrento Therapeutics, Inc. ($SRNE): 68,474 watchersRead Next:&nbsp; <a href="https://stocktwits.com/news-articles/markets/equity/block-ceo-jack-dorsey-weighs-in-on-election-impact/cJ4EMJ3Raj">Block CEO Jack Dorsey Keeps Fingers Crossed Over Regulatory Environment As Trump Makes A Comeback</a>For updates and corrections email newsroom@stocktwits.com&nbsp;

GOP lawmakers are divided over drug pricing reforms.

Will Trump 2.0 Nurse Biotechs Back To Health: 10 Stocks Retail Is Watching

Less stringent requirements in pharmaceuticals and biotechnology could help by prompting accelerated drug approvals.

iBio, Inc. is an AI-driven innovator that develops next-generation biopharmaceuticals using computational biology and 3D-modeling of subdominant and conformational epitopes, prospectively enabling the discovery of new antibody treatments for hard to target cancers, and other diseases. It focuses on decreasing drug failures, shortening drug development timelines and opening up new frontiers against the most promising targets. The company was founded on April 17, 2008 and is headquartered in San Diego, CA.

iBio Inc

Will NVIDIA ($NVDA) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

) beat quarterly earnings? 
 
*Powered by Polymarket

Current Price	$1.16
Prev Close	$1.15
Open	$1.10
Dividend Yield	0.00%
50-Day Moving Average	$1.04
Beta	1.33
Avg. Volume	6.99M
PE Ratio	-0.83

52-Week High	$6.89
52-Week Low	$0.5562
Market Capitalization	$26.09M
EPS (Annual)	-$1.75
Price to Book	0.42
Revenue Per Employee	$20,000.00
Enterprise Value/EBITDA	N/A

IBIO
iBio Inc

Feed

News

Sentiment

Fundamentals

Info

Latest IBIO News

IBIOiBio Inc